2
of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19-9 levels.
The sentence as originally published, ''Eligible patients were started on an eight-cycle course of 1,000 mg/m 2 of gemcitabine and 80 mg/m 2 of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19-9 levels,'' is incorrect.
The online version of the original article can be found under doi:10.1245/s10434-014-3486-z.
